There are good drugs to treat drug-sensitive tuberculosis in otherwise healthy, compliant patients, but everyone who treats tuberculosis knows that many of our patients fall outside of this group. Even in this "perfect setting", therapy is too long and intolerance too frequent.
After decades with few or no new medicines for tuberculosis, many drugs and drug-candidates are now being developed, tested, and marketed (1).
The first strategy to find new medications is to look at the currently used antituberculous drugs. Most currently agents have reached their maximal benefit-toxicity dosing (2) . That is, giving higher doses has not been shown to render additional benefit, or higher doses are more toxic.
The exception to this may be the rifampicins. Several studies have shown that blood levels of about half the patients taking these drugs are below the recommended maximum therapeutic blood levels; and the levels seem to be lower in sicker patients (3) . Several studies in mice and humans indicate that higher doses of rifamycins hasten culture conversion. Rifapentine is a promising drug, whose high potency, long duration of activity, ability to kill latent as well as active bacilli, and low toxicity suggest that it will have expanded use in the future (4) . Developing the best treatment for latent tuberculosis is still in evolution.
Other drugs in current use that were not primarily designed for tuberculosis include the quinolones.
Moxifloxacin, gatifloxacin, and levofloxacin have now taken a place as the standard treatment of drug-resistant tuberculosis (5) . Moxifloxacin is the most studied drug and appears to be able to replace isoniazid (6) or ethambutol (7), but it cannot replace rifampin or pyrazinamide.
Linezolid is an oxazolidinone whose antimycobacterial properties were known before it was marketed. It is used 
